Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. has demonstrated an improvement in the efficacy of its lead therapy, TARA-002, evidenced by 100% durability and an 80% salvage rate upon re-induction as observed in the 6-month clinical data. Additionally, the Phase 2 trial results indicate significant improvements in liver health through the addition of intravenous choline chloride, showcasing its potential to mitigate intestinal failure-associated liver disease. These positive developments in clinical efficacy and safety, combined with the potential for competitive positioning in the market, support a bullish outlook for Protara Therapeutics's stock.

Bears say

Protara Therapeutics reported a net loss of $12.7 million, translating to a loss of $0.48 per share in the fourth quarter of 2024, which raises concerns about the company's financial health. Despite exhibiting promising early signals for TARA-002 in non-muscle invasive bladder cancer (NMIBC), the stock trades at a significant discount compared to peers, suggesting potential undervaluation amidst financial instability. The competitive landscape for NMIBC therapies and ongoing challenges related to the availability of choline for patients suffering from intestinal-failure associated liver disease (IFALD) may further hinder the company's growth prospects.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.